DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Top 10 Bioprocess Technology Market by Cell Culture, Cell Expansion, Cell Counting, Cell Line Development, Flow Cytometry, Single-Use Bioprocessing, Biologics Safety Testing, Tangential Flow Filtration, Virus Filtration & Region - Forecast to 2021" report to their offering.
The top 10 bioprocess technology market is expected to USD 71.03 Billion by 2021 from USD 39.30 Billion in 2016, at a CAGR of 12.4% between 2016 and 2021.
Growth in the biopharmaceutical industry, increase in R&D spending, rising demand for vaccine production, and technological advancements form important growth drivers for this market during the forecast period. The rising opportunities in emerging market and increasing pharmaceutical outsourcing provide significant growth opportunities for players operating in the top 10 bioprocess technology market.
The report provides an overall understanding of the global top 10 bioprocess technology market. It segments the global market on the basis of type and region. On the basis of type, the market is segmented into cell culture, cell expansion, cell counting, cell line development, flow cytometry, single-use bioprocessing, biologics safety testing, virus filtration, tangential flow filtration, and pyrogen testing. In 2016, the cell culture segment is expected to account for the largest share of the global top 10 bioprocess technology market. The largest share of this segment is primarily attributed to the repeated purchase of consumables as compared to equipment and increase in funding for cell-based research.
The major players in top 10 bioprocess technology market include GE Healthcare (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Lonza Group AG (Switzerland), Merck Millipore (Germany), Sartorius Stedim Biotech S.A (France), Corning, Inc. (U.S.), Bio-Rad Laboratories (U.S.), and Charles River Laboratories (U.S.).
- Growth in the Biopharmaceutical Industry
- Increase in R&D Spending in Developed Economies
- Increasing Demand for Vaccines
- Technological Advancements
- Growing Prevalence of HIV and Cancer
- Increasing Number of New Drug Launches
- Stringent Regulatory Policies
- High Cost of Instruments
- Rising Opportunities in Emerging Markets
- Increasing Pharmaceutical Outsourcing
- Requirement of High Capital Investments to Set Up New Production Facilities
- Complexities in Reagent Development
For more information about this report visit http://www.researchandmarkets.com/research/jglv3h/top_10_bioprocess